RFI grants exclusive sublicense to GeneWize Life Sciences, a wholly owned subsidiary of GeneLink, Inc. to market AC-11(R) in the Affiliate Direct Selling Channel
NEW YORK, Aug. 11 /PRNewswire-FirstCall/ -- Optigenex Inc. (OTC:OPGX.OB) (BULLETIN BOARD: OPGX.OB) announced today the signing with RFI, LLC of two exclusive Supply and Trademark License Agreements for the territory of North America to market AC-11(R). The Agreement will allow RFI, LLC to market products under the registered trademark AC-11(R) (Formerly known as C-Med- 100(R)) and capitalize on the scientifically validated qualities of the patented AC-11(R) compound. In third party pre-clinical and scientific studies, AC-11(R) has been shown to help the body's natural ability to repair damage to DNA due to multiple causes, including the harmful effects of UV radiation from exposure to the sun, stress, toxins and environmental pollution. Additional studies moreover have established the effectiveness of AC-11(R) as an inhibitor of pro-inflammatory agents, and as a natural immune stimulator.
Jeff Wuagneux, President and CEO of RFI, LLC, said, "RFI and our Sub-Licensee GeneWize, a wholly owned subsidiary of GeneLink, Inc. (OTC Bulletin Board: GNLK.OB) are particularly enthusiastic about the present and future prospects related to AC-11(R) based formulas for distribution into the Direct to Healthcare Practitioner channel under RFI's PhytoRich brand as well as a primary component of the GeneWize Direct Selling genetic testing model, and we are fortunate to have aligned ourselves with a reputable science based company such as Optigenex."
Daniel Zwiren, President and CEO of Optigenex Inc., said, "The signing of these two agreements marks a significant milestone for Optigenex Inc. towards our goal of achieving brand awareness and continued validation of our technology through the adoption by market leaders. RFI has devoted significant time and resources in positioning AC-11(R) with a company that owns patented technology focused on targeting a unique supplement program based on a specific and personal genetic profile. We believe the future of the dietary supplement industry will focus on targeted supplement programs and we are confident that AC-11(R) will play an important role in the years ahead."
Financial Terms Were Not Disclosed.
About RFI, LLC:
RFI, LLC is a U.S. based (New York, Colorado) Life Science Development and Commercialization Company offering a Pipeline of Novel Compounds and proprietary science-based nutritional bioactive formulas for the Food, Dietary Supplement, Practitioner, Direct Selling and Direct to Consumer channels.
About Optigenex Inc.:
Optigenex Inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk product featuring AC-11(R), its patented compound, as its core ingredient. AC-11(R) is the bioactive form of the medicinal herb Uncaria tomentosa. In data derived from over 10 years of pre-clinical and scientific study and development, AC-11(R) has been shown to help the body's natural ability to repair its own DNA, enhance the immune system function and inhibit pro-inflammatory agents.
For more information about Optigenex please visit the company's website at http://www.optigenex.com/
NOTE: These statements have not been evaluated by the Food and drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
DATASOURCE: Optigenex Inc.
CONTACT: Dan Zwiren of Optigenex Inc., +1-201-638-3810
Web site: http://www.optigenex.com/
GeneLink, Inc. (USOTC:GNLKQ)
Historical Stock Chart
5 Years : From Oct 2012 to Oct 2017